Foghorn Therapeutics announced new preclinical data presentations for its selective cancer drug candidates, including the SMARCA2 inhibitor FHD-909 and degraders targeting CBP, EP300, and ARID1B, at the 2026 AACR Annual Meeting. These data highlight potential treatment advances for difficult cancers like SMARCA4-mutant lung cancer and ER+ breast cancer. The company is advancing FHD-909 in clinical trials with Lilly and aims to explore combination therapies with anti-PD-1 antibodies. The presentations underscore Foghorn's innovative approach to targeting chromatin regulatory proteins, which may improve outcomes for patients with unmet medical needs.
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
